Stockholm, Sweden, September 3, 2024 – Following the announcement by Asahi Kasei Corporation (“Asahi Kasei”) on September 2, 2024 that it controls more than 90 percent of the outstanding shares of Calliditas Therapeutics AB (Nasdaq: CALT) (“Calliditas” or the “Company”), and declared its offers to purchase all of the outstanding Common Shares and ADSs of Calliditas […]
Transaction values animal health therapeutics pioneer at up to $520 million Novo Holdings co-led Invetx Series B financing round in 2022 Boston, MA, July 18, 2024 – Novo Holdings A/S, a leading international life sciences investor, today announced that its portfolio company, Invetx, has agreed to be acquired by Dechra Pharmaceuticals Limited (“Dechra”), an international veterinary […]
The Board of Directors of Calliditas Therapeutics AB (publ) unanimously recommends that the shareholders and holders of American Depositary Shares (“ADS”) of Calliditas Therapeutics AB (publ) (jointly the “Securityholders”) accept the public tender offer by Asahi Kasei Corporation. Background This statement is made by the Board of Directors (the “Board”) of Calliditas Therapeutics AB (publ) […]
Novo Holdings A/S, a leading global life sciences investor, today announced that it has agreed to acquire Ellab from EQT. Headquartered in Hillerød, Denmark, Ellab (“Ellab”) provides validation and monitoring solutions and services for biotech and pharmaceutical processes. Its solutions and services measure and document parameters such as temperature, pressure and carbon dioxide, which helps […]
NanoBone® technology complements Biocomposites’ absorbable bone regeneration products Artoss to benefit from Biocomposites established, global distribution network Keele, UK, 6 June 2023 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for regenerating bone and managing infection in bone and soft tissue, today announces the acquisition of Artoss GmbH (Artoss), […]
